{"entity":{"id":"nct05367778","kind":"trial","name":"Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HS-10370 in advanced solid tumours, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.","summary":"Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05367778 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 176 participants planned, started 2022-06-03 and due to reach its primary completion in 2025-04-30. Interventions recorded: HS-10370.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05367778","url":"https://clinicaltrials.gov/study/NCT05367778"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05367778","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10370 Monotherapy in Patients with Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","enrolled":176,"outcomes":[]},"route":"/trials/nct05367778/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}